| Course | NU 636 Advanced Pharmacology |
|---|---|
| Unit | Unit 2 |
| Paper type | Prescribing rationale |
| Length | About 1,060 words, 6 pages |
| Format | APA 7 student paper |
| School | Herzing University |
| Program | MSN Family Nurse Practitioner |
| Updated | October 2026 |
Free sample paper for NU 636 Unit 2
Prescribing Rationale for an Acute Gout Flare in a 66-Year-Old Man With Stage 3b Kidney Disease on an Anticoagulant
Student Name
Department of Nursing, Herzing University
NU 636: Advanced Pharmacology
Instructor Name
January 28, 2026
Prescribing Rationale for an Acute Gout Flare in a 66-Year-Old Man With Stage 3b Kidney Disease on an Anticoagulant
The Patient and the Problem
Mr. N., a composite 66-year-old retired postal carrier, presents with 20 hours of severe pain, swelling, and redness of the right first metatarsophalangeal joint. He had two similar episodes in the past three years, each treated elsewhere with naproxen. He has chronic kidney disease stage 3b, with an estimated glomerular filtration rate of 38 mL/min/1.73 m2 on labs from last month, hypertension, and atrial fibrillation. His medications are apixaban 5 mg twice daily, atorvastatin 40 mg daily, amlodipine 10 mg daily, and hydrochlorothiazide 12.5 mg daily. He has no diabetes and no history of peptic ulcer. His temperature is 99.3 F, and the joint is too tender to bear the weight of a sheet. The presentation is typical of a gout flare, and he has a documented prior diagnosis with crystals seen on aspiration four years ago. Infection is considered and judged unlikely given his typical history, recurrence, and lack of systemic toxicity, with a plan to aspirate if he does not improve as expected.
The goal is rapid relief of the flare within days, with the fewest adverse effects in a man whose kidney function and anticoagulant narrow every option.
The Candidate Agents
Three drug classes are recommended as first-line options for a gout flare, and the choice among them is meant to be made on patient factors (FitzGerald et al., 2020). A nonsteroidal anti-inflammatory drug such as naproxen would offer fast relief and is the agent he has used before with success. Colchicine would offer an effective oral option that works best when started within 36 hours of onset, which he is inside. An oral glucocorticoid such as prednisone would offer relief equivalent to a nonsteroidal anti-inflammatory drug, shown in a randomized trial comparing prednisolone with naproxen (Janssens et al., 2008). An intra-articular glucocorticoid injection is a fourth reasonable option for a single large joint. Interleukin-1 inhibitors are reserved for patients in whom all of these are ineffective or contraindicated, and because Mr. N. has usable options among the first-line agents, that class is not part of today's decision. Naming it, and the reason it is set aside, keeps the list of candidates honest rather than conveniently short.
Elimination, One Agent at a Time
Naproxen is eliminated first, for two reasons drawn from the case. Nonsteroidal anti-inflammatory drugs reduce renal prostaglandin synthesis, which the kidney relies on to maintain blood flow when function is already reduced; in a man with an eGFR of 38 who also takes a thiazide diuretic, a course of naproxen risks an acute decline in kidney function. And nonsteroidal anti-inflammatory drugs impair platelet function and injure gastric mucosa, adding substantially to the bleeding risk of apixaban. The fact that it worked before does not outweigh a risk that has increased since then.
Colchicine is eliminated second, although it is closer. At his kidney function it can be used for a flare, but the margin between effective and toxic doses is narrow, and colchicine is a substrate of cytochrome P450 3A4 and P-glycoprotein. His atorvastatin is metabolized by the same enzyme, and combined use in reduced kidney function has been associated with myopathy (Rosenthal & Burchum, 2021). None of these factors is an absolute bar alone, but together, and in a man who wants to avoid another laboratory visit, they make colchicine the riskier of the two remaining options.
The intra-articular injection is kept as an alternative rather than eliminated. It avoids systemic effects entirely, but it requires an appointment for the procedure, and the patient's anticoagulant raises the bleeding risk of joint aspiration and injection somewhat, though it is not usually a contraindication. He prefers to start treatment today at home, and his preference is a legitimate factor in a choice between options of similar effectiveness.
The Chosen Agent: Dose, Route, Frequency, and Duration
Prednisone 35 mg by mouth once daily with breakfast for 5 days, then stop, dispense 25 mg and 10 mg tablets as needed to make the dose, no refills. The dose and duration follow the regimen shown by Janssens et al. (2008) to be equivalent in pain relief to naproxen, and a short course of five days does not require a taper. Oral glucocorticoids need no dose adjustment for kidney function, they do not interact meaningfully with apixaban through the coagulation pathway, and a short course carries low risk in a man without diabetes. Morning dosing reduces sleep disturbance. He is advised to take it with food, to expect a possible increase in appetite or mild mood change, and to use ice and elevate the foot.
The thiazide is addressed as part of the rationale, not left untouched. Thiazide diuretics raise serum urate and increase the risk of recurrent flares. Changing his antihypertensive regimen is not urgent today, but a plan is made to consider replacing hydrochlorothiazide at the follow-up visit, in coordination with his blood pressure goals.
Monitoring
Baseline: blood pressure and a fingerstick glucose today, because glucocorticoids can raise both. A telephone check at 48 to 72 hours asks whether pain has improved by at least half. Temperature is recorded at that call; a fever above 100.4 F, spreading redness, or worsening pain would prompt same-day review and joint aspiration to exclude septic arthritis. A serum urate is drawn two to four weeks after the flare settles, when it more accurately reflects his baseline, along with creatinine.
What Would Change the Plan
If pain has not improved by half at 72 hours, the diagnosis is reconsidered first, and the joint is aspirated, before any change of drug. If the flare is confirmed and resistant, intra-articular injection becomes the next step. If his glucose rises above 200 mg/dL on prednisone, the course is shortened and colchicine at a reduced dose becomes the alternative, with atorvastatin temporarily held. If he has two or more flares a year, which his history suggests he is approaching, he meets the threshold for urate-lowering therapy, and allopurinol, started at a low dose appropriate for his kidney function and titrated to a serum urate below 6 mg/dL, would be discussed at the follow-up visit (FitzGerald et al., 2020). Treating the flare and preventing the next one are separate decisions, and this rationale covers only the first while naming when the second begins.
References
FitzGerald, J. D., Dalbeth, N., Mikuls, T., Brignardello-Petersen, R., Guyatt, G., Abeles, A. M., Gelber, A. C., Harrold, L. R., Khanna, D., King, C., Levy, G., Libbey, C., Mount, D., Pillinger, M. H., Rosenthal, A., Singh, J. A., Sims, J. E., Smith, B. J., Wenger, N. S., ... Neogi, T. (2020). 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care & Research, 72(6), 744-760. https://doi.org/10.1002/acr.24180
Janssens, H. J. E. M., Janssen, M., van de Lisdonk, E. H., van Riel, P. L. C. M., & van Weel, C. (2008). Use of oral prednisolone or naproxen for the treatment of gout arthritis: A double-blind, randomised equivalence trial. The Lancet, 371(9627), 1854-1860. https://doi.org/10.1016/S0140-6736(08)60799-0
Rosenthal, L. D., & Burchum, J. R. (2021). Lehne's pharmacotherapeutics for advanced practice nurses and physician assistants (2nd ed.). Elsevier.
NU 636 Unit 2 instructions, in plain terms
The Unit 2 assignment asks you to select a medication for a patient case and justify the choice against alternatives. Expect to identify the treatment options a guideline supports, then explain why each is or is not suitable for this patient, using factors such as kidney function, age, other medications and comorbid conditions. The chosen drug must be written completely: dose, route, frequency, duration and quantity. Monitoring should state what will be checked, when and why. Many sections ask what would make you change the plan, such as a failure to respond by a set time. Sources should include a current guideline and evidence on the chosen agent, cited in APA 7. The classroom rubric sets length. The patient should be composite, and the rationale should stay focused on one prescribing decision.
Inside the NU 636 Unit 2 example
The paper starts with the patient's flare and the details that will drive the decision: kidney function, the anticoagulant, two earlier episodes and no diabetes. The candidate section lists the guideline's three first-line options and states that the choice depends on patient factors. Elimination takes each agent in turn. Naproxen is removed because it reduces renal prostaglandins and adds bleeding risk with the anticoagulant. Colchicine is set aside because of reduced clearance at this kidney stage and an interaction affecting its levels. The chosen agent section gives prednisone with full prescribing details and cites a trial showing it is as effective as an anti-inflammatory for gout. Monitoring includes baseline glucose and blood pressure and a phone check at 48 to 72 hours. The final section explains when the diagnosis would be reconsidered and the joint aspirated.
NU 636 Unit 2 rubric: what full points look like
Herzing rubrics for a prescribing rationale commonly score assessment of patient factors, consideration of alternatives, the selected regimen, monitoring and evaluation, use of evidence and writing. Patient factor points require kidney function, current medications and comorbidities to be identified and applied. Alternatives are credited when each option is weighed for this patient rather than dismissed in a sentence. The selected regimen is often weighted heavily, and full points go to a complete, correct prescription supported by a guideline or trial. Monitoring points depend on specific checks with timing. Evaluation earns credit when the paper states a measurable response and what happens if it is not reached. Writing points cover APA format, current sources and a logical order that moves from options to decision.
Common NU 636 Unit 2 mistakes, and how to avoid them
Rationales often lose points when the chosen drug is named early and the alternatives are dismissed afterward without real reasons. Students also omit the full prescription, leaving out duration or quantity. Kidney function is frequently mentioned but not used, even though it changes the safe choice. Interactions with the patient's existing medications, here an anticoagulant, are a common blind spot. Monitoring is often generic or missing. Another weakness is failing to say what would change the plan, which leaves the evaluation criterion unearned. Guidelines should be cited by organization and year, not described as current recommendations without a source. Finally, keep the paper to one decision; adding long-term urate lowering when the prompt asks about the flare spreads the length too thin.
Get a NU 636 Unit 2 example written to your instructions
Send the Unit 2 instructions and the rubric from your NU 636 classroom, plus the case or the condition the rationale has to address. We write a custom example against those criteria, with the alternatives eliminated on the evidence and monitoring given intervals, and return it in 24 to 48 hours. The first custom sample is free.
More NU 636 papers and FNP samples
- NU 636 Unit 1: Drug class profile
- NU 636 Unit 3: Pharmacotherapy plan
- NU 636 Unit 4: Patient education handout
- NU 636 Unit 5: Drug therapy paper
- NU 636 Unit 6: Discussion post
- NU 636 Unit 7: Drug comparison paper
- NU 636 Unit 8: Comprehensive case study
- NU 632 Unit 2: Growth and development assessment
- NU 610 Unit 2: Focused exam write-up
- NU 611 Unit 2: Differential diagnosis paper
- NU 621 Unit 2: Discussion post
NU 636 Unit 2 questions, answered
How many alternatives should the rationale consider?
Enough to make the decision look contested, which is usually two or three besides the agent selected. Each has to be genuinely defensible for this patient, because eliminating a poor option demonstrates nothing. More than four tends to thin the reasoning, since every candidate needs a stated reason for entering the conversation and a stated reason for leaving it.
Can I cite clinical guidelines in this course?
In most sections yes, and they are often expected for anything with an established standard of care. What loses marks is citing a guideline in place of reasoning, as though the recommendation ends the discussion. Use the guidance to establish what is reasonable, then do the work the guidance cannot do, which is applying it to the specific factors in your composite patient.
What counts as a reassessment trigger?
Anything that would honestly move the plan: a laboratory result crossing a defined value, an adverse effect appearing, a lack of response by a stated point, a new interacting medication or a change in organ function. Name the trigger and the response together. A trigger with no consequence attached reads as a hedge instead of the clinical thinking being asked for.
Where can I find a free NU 636 Unit 2 sample paper?
The complete NU 636 Unit 2 rationale is published on this page free, including the elimination of each option, the full prednisone prescription and the monitoring plan. For a different case, we can write a free custom rationale around it, usually in two days or less.
How do I write a prescribing rationale for NU 636?
List the options a guideline supports, then rule each in or out using the patient's kidney function, current drugs and conditions. Write the chosen drug in full with dose, route, frequency, duration and quantity, then say what you will monitor and what would change the plan.